Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.

ABSTRACT:

Purpose

Although gemcitabine-based chemotherapy is most recommended for pancreatic ductal adenocarcinoma (PDAC), its effectiveness is limited because of drug resistance. Given thalidomide's anti-tumor effects in solid tumors, we investigated the effect of avadomide, a novel thalidomide analog, on PDAC and explored its anti-tumor mechanisms.

Methods

PDAC cell lines, including gemcitabine-resistant (GR) clones derived from MiaPaCa2 cells, were used to evaluate the effects of avadomide. An annexin V assay, a cell cycle assay, and western blot analysis were performed to explain the mechanism of avadomide as an anti-tumor reagent. Moreover, we investigated the anti-tumor effect on tumor growth using a subcutaneous xenograft murine model.

Results

Avadomide showed anti-tumor

SUBMITTER: Nishi H 

PROVIDER: S-EPMC10435408 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature